WATERTOWN, Mass.—EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, has appointed John Landis, PhD, MS, to its board of directors. Landis, a veteran pharmaceutical sciences executive, has led development functions including pharmacy, analytical chemistry, process chemistry, biotechnology, devices, clinical supplies and quality assurance. Landis also led the preclinical functions of toxicology, drug metabolism and pharmacokinetics, and laboratory animal care. He will serve on the science committee, according to an announcement earlier this week.

“Dr. Landis brings more than 30 years of pharmaceutical research and development experience to our board with a proven track record of leading cross-functional global teams and managing preclinical and clinical asset portfolios,” Nancy Lurker, president and chief executive officer, said in the announcement. “Our team will greatly benefit from Dr. Landis’ development expertise and guidance from his deep and diverse career from academia to the pharmaceutical industry.”

Landis said he believes EyePoint is entering “a new chapter of growth with the pending U.S. commercial launches for two ophthalmic products” next year. He added, “I look forward to guiding the company as it executes on its strategic and commercial corporate goals in support of the transition to a commercial-stage specialty pharmaceutical company with a pipeline of innovative products for ocular diseases.”

Landis most recently served as a director for Bioanalytical Systems Inc., serving as chairman of its board of directors. He previously served as senior vice president, pharmaceutical sciences, at Schering-Plough.

EyePoint Pharmaceuticals (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.

With the approval of Yutiq, the company has developed five of only six FDA-approved sustained-release treatments for eye diseases, according to the announcement.